ORIGINAL RESEARCH article
Front. Endocrinol.
Sec. Bone Research
Volume 16 - 2025 | doi: 10.3389/fendo.2025.1625944
This article is part of the Research TopicMolecular and Cellular Mechanisms of Bone RemodelingView all articles
Inhibition of histone methyltransferase G9a promotes the osteogenic potential of bone-derived stem cells in diabetic-osteoporosis by regulating the LINC00657/miR-204-5p/IGFBP5 pathway
Provisionally accepted
- 1Shanghai University of Traditional Chinese Medicine, shanghai, China
- 2Graduate School, Shanghai University of Traditional Chinese Medicine, shanghai, China
- 3Zhoupu Hospital, Shanghai University of Medicine and Health Sciences, Shanghai, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Bone mesenchymal stem cells (BMSCs) from patients with diabetes often exhibit reduced osteogenic potential. This study aimed to investigate the mechanism of action of G9a, known as euchromatic histone lysine methyltransferase 2 (EHMT2), identify its key responsive long non-coding RNA in diabetic osteoporosis (DOP), and evaluate the effectiveness of the G9a inhibitor (UNC0638).Methods: The expression level of G9a in bone-derived MSCs (BMSCs) from osteoporosis patients with or without T2DM (T2DM-BMSCs, CON-BMSCs) was detected, and osteogenic differentiation was evaluated by osteogenic genes, ALP activity and calcification level. The key lncRNA, LINC00657, was screened based on previous transcriptome sequencing, qPCR and gene overexpression assay. The downstream miRNA and the target gene of LINC00657 were identified through transcriptome sequencing, bioinformatics analysis, dual luciferase reporter assay and gene overexpression assay. Rat DOP was constructed, and micro-CT, histochemical staining, immunofluorescence and qPCR were used to investigate the mechanism of UNC0638.Results: G9a expression was increased and LINC00657 expression was decreased in T2DM-BMSCs, compared with CON-BMSCs. UNC0638 treatment improved the osteogenic potential of T2DM-BMSCs and reversed the downregulation of LINC00657. LINC00657 overexpression reverses the inhibitory effect of EHMT2 on osteogenic differentiation. miR-204-5p and IGFBP5 were screened as downstream molecules of LINC00657. LINC00657 was able to sponge miR-204-5p and upregulated IGFBP5 expression, thereby promoting osteogenesis in T2DM-BMSCs.UNC0638 treatment alleviated osteoporosis in DOP rats, whereas LINC00657 knockdown inhibited its effect in vivo.Conclusions: G9a inhibits the osteogenic potential of T2DM-BMSCs by regulating the LINC00657/miR-204-5p/IGFBP5 pathway and UNC0638 may be a potential agent for DOP treatment.
Keywords: G9a inhibitor, Diabetic osteoporosis, LINC00657, miR-204-5p, IGFBP5
Received: 11 Jun 2025; Accepted: 18 Jul 2025.
Copyright: © 2025 Qiao, Wang, Fan, Gao, Wang, Guo and Xia. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Sheng-li Xia, Zhoupu Hospital, Shanghai University of Medicine and Health Sciences, Shanghai, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.